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Abstract
Background:  The continuous spread of penicillin-resistant pneumococci represents a permanent
threat in the treatment of pneumococcal infections, especially when strains show additional
resistance to quinolones. The main objective of this study was to determine a treatment modality
impeding the emergence of quinolone resistance.
Results:   Exposure of a penicillin-resistant pneumococcus to increasing concentrations of
trovafloxacin or ciprofloxacin selected for mutants resistant to these drugs. In the presence of sub-
inhibitory concentrations of vancomycin, development of trovafloxacin-resistance and high-level
ciprofloxacin-resistance were prevented.
Conclusions:  Considering the risk of quinolone-resistance in pneumococci, the observation
might be of clinical importance.
Background
Since the late seventies, the worldwide emergence of
penicillin-resistant pneumococci has jeopardized the ef-
ficacy of β -lactam antibiotics, in life threatening infec-
tions such as meningitis or pneumonia [1]. Moreover,
penicillin-resistant pneumococci are often resistant to
multiple other drugs, thus restricting the choice of alter-
native compounds [2]. Therefore, new anti-pneumococ-
cal drugs should combine the abilities to (i) rapidly
inhibit and kill the target organisms, (ii) penetrate in var-
ious body compartments, including the cerebrospinal
fluid, and (iii) impede resistance development against
the new compounds. Newer quinolones with good anti
gram-positive activity, including trovafloxacin, might
fulfill these criteria. However, quinolone-resistant pneu-
mococci can arise by acquisition of only one or two mu-
tations in the genes of the quinolone targets, i.e., the
topoisomerase IV (parC and parE) and the gyrase (gyrA
and gyrE) [3,4,5,]. This mechanism of resistance is much
less complicated than acquisition of resistance to penicil-
lin by transformation with major gene sequences for PB-
Ps. One would therefore expect that the activity of
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quinolones against pneumococci is already jeopardized.
Indeed, recent data support this notion [3].
Recently, we observed that addition of vancomycin to
trovafloxacin improved the bactericidal activity of the
quinolone against penicillin-resistant pneumococci both
in vitro and in rabbits with experimental meningitis [6].
We now demonstrate that sub-inhibitory concentrations
of vancomycin (1/4 MIC: 0.03 mg/L), that did not affect
the quinolone MIC per se, also drastically prevented re-
sistance to ciprofloxacin, and totally prevented resist-
ance to trovafloxacin. The observation deserves
attention because it might be of clinical relevance.
Results
Repeated exposure of WB4 to stepwise increasing con-
centrations of either trovafloxacin or ciprofloxacin re-
sulted in resistance development against both drugs.
Figure 1 indicates that the MIC of trovafloxacin had in-
creased by 32-fold (MIC 4 mg/L) after only five passages.
Likewise, the MIC of ciprofloxacin increased 16-fold (8
mg/L) after only three antibiotic passages. In sharp con-
trast, addition of sub-inhibitory concentrations (1/4 the
MIC: 0.03 mg/L) of vancomycin to trovafloxacin com-
pletely prevented the emergence of mutants resistant to
this drug, and the MIC of trovafloxacin remained un-
changed for up to eight cycles (Figure 1). Moreover, addi-
tion of vancomycin to ciprofloxacin also reduced
resistance development against this compound, albeit
not to the same extent as for trovafloxacin. Indeed, a
slight increase to 2-fold the MIC (1 mg/L) was observed
in this experiment (Figure 2). Addition of 1/4 the MIC of
vancomycin did not affect the MIC of the test quinolones
and resistance to vancomycin has not been observed in
quinolone-resistant mutants either (Table 1).
As previously described, there was a certain amount of
cross-resistance between the two test quinolones. Table
1 indicates that resistance to trovafloxacin was accompa-
nied by a parallel increase in the ciprofloxacin MIC (from
0.5 mg/L to > 32 mg/L). On the other hand, selection of
resistance with ciprofloxacin only marginally affected
the MIC of trovafloxacin (from 0.12 to 0.25 mg/L).
The difference between these cross-resistance patterns
most likely relied in the specific mutations selected by
the two drugs. Table 2 presents the mutations in the
topoisomerase IV (parC and parE) and gyrase (gyrA and
gyrB) genes observed in resistant mutants selected with
either of the compounds. Trovafloxacin selected muta-
tions in the parC and the gyrA genes. The parC mutation
(Ser79→ Phe) was previously described [11,12,13]. Two
other parE (Asp435→ Asn, and Ile460→ Val) were re-
cently observed in a clinical isolate of trovafloxacin-re-
sistant pneumococcus [14], but did not appear in the
present experiments. The gyrA mutation (Ser81→ Phe)
has been reported as well [5]. This mutation resembles a
gyrA (Ser83→ Phe) mutation described in ciprofloxacin-
resistant pneumococci [15], and is likely to be responsi-
ble for the cross-resistance pattern between trova-
floxacin and ciprofloxacin.
In contrast, resistance to ciprofloxacin was somewhat
different. The parC mutation (Ser79→ Tyr) was relatively
conserved when compared to the parC mutation selected
Figure 1
shows selection of trovafloxacin resistant mutants of Strepto-
coccus pneumoniae WB4 exposed to stepwise increasing con-
centrations of trovafloxacin alone or in combination with
sub-MIC concentration (1/4 MIC) of vancomycin.
Figure 2
shows selection of ciprofloxacin resistant mutants of Strepto-
coccus pneumoniae WB4 exposed to stepwise increasing con-
centrations of ciprofloxacin alone or in combination with
sub-MIC concentration (1/4 MIC) of vancomycin.BMC Microbiology (2001) 1:9 http://www.biomedcentral.com/1471-2180/1/9
by trovafloxacin (Ser79→ Phe). Indeed, both substitu-
tions (Tyr and Phe) involve aromatic acids that differ
only by one hydroxyl group. On the other hand, the GyrB
mutation (Asp435→ Glu) has been described in cipro-
floxacin-resistant derivatives, but not in trovafloxacin-
resistant clones [15]. Therefore, it is likely that this mu-
tation cannot confer cross-resistance to trovafloxacin.
Discussion
Sub-inhibitory concentration of vancomycin prevented
the selection of all these mutations, except for the low
level resistance mutation to ciprofloxacin (Table 2).
Since these vancomycin concentrations did not affect the
quinolones' MICs, it was unlikely that mutation preven-
tion was merely due to a combined bacteriostatic effect of
the two drugs. An other conceivable explanation for this
phenomenon might be an increased intracellular pene-
tration of the quinolones by addition of the cell wall ac-
tive antibiotic. This would lead to intracellular antibiotic
levels above the mutant prevention concentration (MPC)
impeding the emergence of mutations [16]. However,
this hypothesis is less probable because one would ex-
pect a change of the MIC in presence of vancomycin (see
Table 1). On the other hand, we did previously show that
the combination of vancomycin with quinolones synergi-
cally increased the bactericidal effect of these drugs [6].
Therefore, resistance prevention might be due to im-
proved bactericidal killing at the MIC and supra-MIC
concentrations, thus lowering the bacterial population
below the critical level that allows selection for chromo-
somal mutations (i.e., below 106-108 CFU). This was in-
deed the case both in vitro and in rabbits with
experimental meningitis [6].
Conclusions
The data observed here are reminiscent of the synergic
activity of cell wall active antibiotics and aminoglyco-
sides in enterococci and other gram-positive pathogens.
Although the mechanism of this synergism is not entirely
clear, it is important both to prevent resistance and im-
prove therapeutic efficacy in severe infections. A similar
model could hold true with the combination of cell wall
inhibitors and trovafloxacin or other quinolones in pneu-
mococcal infections. Therefore, the present observation
with vancomycin and quinolones might be of clinical rel-
evance both for resistance prevention and treatment ef-
ficacy. Moreover, it opens the avenue to other drug
combinations.
Table 1: MICs of trovafloxacin and ciprofloxacin alone and in combination with subinhibitory concentrations of vancomycin
MIC(mg/L)
WB4 WB4C WB4T WB4C+V WB4T+V
Ciprofloxacin 0.5 8 >32 1 1
Ciprofloxacin + 0.5 8 >32 1 1
Vancomycin (1/4 MIC)
Trovafloxacin 0.12 0.25 4 0.25 0.12
Trovafloxacin + 0.12 0.25 4 0.25 0.12
Vancomycin (1/4MIC)
Vancomycin 0.12 0.12 0.12 0.12 0.12
WB4: quinolone-susceptible but penicillin-resistant parent pneumococcus; WB4 C: ciprofloxacin-resistant derivative selected by passages on this 
drug; WB4 T: trovafloxacin-resistant derivative selected by passages on this drug; WB4 C+V or WB4 T+V: same as above cycled in presence of 
subinhibitory concentrations of vancomycin.
Table 2: Mutations in topoisomerase IV (ParC and ParE) and gy-
rase (GyrA and GyrB) genes before and after cyclic exposure to 
ciprofloxacin, trovafloxacin, or either of these drugs plus vanco-
mycin in a penicillin-resistant pneumococcal strain
Strain ParC ParE GyrA GyrB
WB4 None none none none
WB4C Ser79 →  Tyr none none Asp435 →  Glu
WB4T Ser79 →  Phe none Ser81 →  Phe none
WB4 C+V Ser79 →  Tyr none none none
WB4 T+V None none none none
WB4: quinolone-susceptible but penicillin-resistant parent pneumo-
coccus; WB4 C: ciprofloxacin-resistant derivative selected by passag-
es on this drug; WB4 T: trovafloxacin-resistant derivative selected by 
passages on this drug; WB4 C+V or WB4 T+V: same as above cy-
cled in presence of subinhibitory concentrations of vancomycin.BMC Microbiology (2001) 1:9 http://www.biomedcentral.com/1471-2180/1/9
Materials and Methods
Antibiotics and MIC determination
Trovafloxacin was provided by Pfizer Inc. (Groton,
Conn.), ciprofloxacin was purchased from Bayer AG
(Wuppertal, Germany), and vancomycin was purchased
from Eli Lilly (Geneva, Switzerland). WB4 is a penicillin-
resistant isolate (MIC: 4 mg/L) serotype 6 originally iso-
lated from a patient with pneumonia at the University
Hospital of Berne, Switzerland, and was grown in C+Y
medium [7]. MICs were determined by broth macrodilu-
tion methods [8]. The MIC was defined as the lowest
concentration that inhibited visible growth after 12 and
24 h of incubation at 37°C.
Selection of quinolone-resistant derivatives in vitro
Experiments were designed to test the tendency of trov-
afloxacin and ciprofloxacin to select resistant strains in
liquid cultures. Large inocula (107-108 CFU/ml) of WB4
were exposed to stepwise increasing concentrations of
antibiotics [9]. Series of tubes containing twofold in-
creasing concentrations of either trovafloxacin or cipro-
floxacin were inoculated with WB4 (107-108 CFU/ml), as
for the MIC determination. After 12 hours of incubation
0.1 ml samples from the tubes containing the highest an-
tibiotic concentration and still showing turbidity were
used to inoculate a new series of tubes containing antibi-
otic serial dilutions. The experiment was performed dur-
ing eight cycles. The MIC was determined after each
cycle.
In further series, the same experimental protocol was
used but vancomycin was added in low concentrations
(0.03 mg/L corresponding to 1/4 MIC) to the tubes con-
taining serial dilutions of either trovafloxacin or cipro-
floxacin. After 12 hours of incubation MIC was
determined as described above in tubes containing only
either trovafloxacin or ciprofloxacin.
Preparation of chromosomal DNA, PCR amplification and 
DNA sequence analysis
Chromosomal pneumococcal DNA was prepared as de-
scribed [10]. PCR-amplification of the parC, parE, gyrA
and gyrB genes were performed according to a published
method [11]. PCR-amplification was performed with a
GeneAmp PCR System 9700 apparatus (Perkin Elmer).
After amplification, PCR products were purified by using
a QIAquick PCR purification kit (Quiagen AG, Basel,
Switzerland). Nucleotide sequencing of the PCR ampli-
cons was carried out by using the ABI PRISM Dye Termi-
nator Cycle Sequencing Ready Reaction kit according to
the protocol of the manufacturer (Perkin Elmer). An ABI
PRISM 377 DNA sequencer was used for sequencing. All
testing was performed in duplicate.
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